The FDA's expanded approval could help GSK maintain its dominance in the RSV market, which includes shots from Pfizer and Moderna.
Source: https://www.cnbc.com/2024/06/07/fda-app ... to-59.html
FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
